Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Nurix Therapeutics announced a strategic partnership with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell blood cancers. Nurix will receive $700 million upfront with potential milestone payments up to $2.3 billion total. The companies will share development costs (40/60 split) and equally split U.S. commercialization profits, while Roche handles international sales with royalties to Nurix. NRIX stock surged 51.23% in premarket trading.